Role of a drug in neonates for the treatment of breathlessness at birth due to retention of fluid in lung
Phase 3
Completed
- Conditions
- Health Condition 1: - Health Condition 2: J988- Other specified respiratory disordersHealth Condition 3: null- Transient tachypnea of newborn
- Registration Number
- CTRI/2017/01/007624
- Lead Sponsor
- St Stephens Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Neonates more than 34 weeks diagnosed as transient tachypnea of newborn according to: - symptoms within first 6 hours after birth
- x-ray chest consistent with retained fetal lung fluid
Exclusion Criteria
1.premature infants less than 35 weeks
2. Neonates with meconium aspiration syndrome or septecemia
3.neonates with hyaline memberane disease
4.neonates with birth asphyxia
5. Neonates with congenital heart disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate improvement in respiratory distress based on respiratory rate and TTN scoreTimepoint: To evaluate improvement in respiratory distress based on respiratory rate and TTN score
- Secondary Outcome Measures
Name Time Method To evaluate duration of Hospitalization in salbutamol treated group compared to standard treatment groupTimepoint: 72 hours;To evaluate oxygen requirement in salbutamol treated group as compared to standard treatment groupTimepoint: 0 hour, 1 hour and 4th hour;To evaluate type and duration of respiratory support required in salbutamol treated group as compared to standard treatment groupTimepoint: 72 hours